Facile identification of dual FLT3-Aurora A inhibitors: A computer-guided drug design approach

Yung Chang Hsu, Yi Yu Ke, Hui Yi Shiao, Chieh Chien Lee, Wen Hsing Lin, Chun Hwa Chen, Kuei Jung Yen, John T.A. Hsu, Chungming Chang, Hsing Pang Hsieh

研究成果: Article同行評審

7 引文 斯高帕斯(Scopus)


Computer-guided drug design is a powerful tool for drug discovery. Herein we disclose the use of this approach for the discovery of dual FMS-like receptor tyrosine kinase-3 (FLT3)-Aurora A inhibitors against cancer. An Aurora hit compound was selected as a starting point, from which 288 virtual molecules were screened. Subsequently, some of these were synthesized and evaluated for their capacity to inhibit FLT3 and Aurora kinase A. To further enhance FLT3 inhibition, structure-activity relationship studies of the lead compound were conducted through a simplification strategy and bioisosteric replacement, followed by the use of computer-guided drug design to prioritize molecules bearing a variety of different terminal groups in terms of favorable binding energy. Selected compounds were then synthesized, and their bioactivity was evaluated. Of these, one novel inhibitor was found to exhibit excellent inhibition of FLT3 and Aurora kinase A and exert a dramatic antiproliferative effect on MOLM-13 and MV4-11 cells, with an IC50 value of 7 nM. Accordingly, it is considered a highly promising candidate for further development. In silico selection: We selected an Aurora hit compound as a starting point, followed by two consecutive computer-guided strategies to rapidly and efficiently modify the side chain and core. These efforts resulted in the identification of a potential FLT3-Aurora A inhibitor for further development to treat acute myeloid leukemia (AML).

頁(從 - 到)953-961
出版狀態Published - 2014 五月

All Science Journal Classification (ASJC) codes

  • 生物化學
  • 分子醫學
  • 藥理
  • 藥物發現
  • 藥理學、毒理學和藥劑學 (全部)
  • 有機化學


深入研究「Facile identification of dual FLT3-Aurora A inhibitors: A computer-guided drug design approach」主題。共同形成了獨特的指紋。